Global Appetite Suppressants Market Analysis By Product Type (Prescription appetite suppressants (Liraglutide, Semaglutide, Tirzepatide, Naltrexone-bupropion, Phentermine-topiramate, Benzphetamine, Diethylpropion, Phendimetrazine, Phentermine), Non-prescription appetite suppressants (Caffeine-based supplements, Green tea extract, Glucomannan, Conjugated Linoleic Acid (CLA), Bitter Orange (Synephrine), Garcinia Cambogia, Others)), By Form (Tablets & capsules, Liquids, Powder, Others), By Route of Administration (Oral, Injectables, Transdermal patches), By Application (Obesity Management, Metabolic Health Support, Sports & Fitness Support, Bariatric Care Support), By Age Group (13-17 years, 18-30 years, 31-50 years, 50 years & above), By Gender (Female, Male), By Distribution Channel (Pharmacies & Drug Stores, Supermarkets & Hypermarkets, Specialty Nutrition & Wellness Stores, Online/e-commerce platforms, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: Nov 2025
- Report ID: 167962
- Number of Pages: 346
- Format:
-
keyboard_arrow_up
-
-
- Novo Nordisk A/S Company Profile
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Orexigen Therapeutics Inc.
- Teva Pharmaceuticals USA
- Taj Pharmaceuticals Company Profile
- Sinew Nutrition
- Gelesis Holdings Inc.
- Sun Pharmaceutical Industries Ltd.
- Innovent Biologics Inc.
- Currax Pharmaceuticals
- Haleon group
- GNC Holdings LLC
- NOW Foods
- Procter & Gamble
- Nestlé S.A Company Profile
- Nature's Bounty
- Unilever Plc Company Profile
- Bayer AG Company Profile
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible